ストックスクリーナーアプリを入手
14.32
0.14%
0.0199
前日終値:
$14.30
開ける：
$14.31
24時間の取引高:
2.66M
Relative Volume:
0.26
時価総額：
$4.49B
収益：
$571.16M
当期純損益:
$-38.10M
株価収益率:
-116.90
EPS:
-0.1225
ネットキャッシュフロー:
$-48.91M
1週間 パフォーマンス:
+0.28%
1か月 パフォーマンス:
+0.28%
6か月 パフォーマンス:
+111.83%
1年 パフォーマンス:
+48.55%
1日の値動き範囲:
$14.29
$14.32
1週間の範囲:
$14.26
$14.32
52週間の値動き範囲:
$5.51
$14.38
Amicus Therapeutics Inc Stock (FOLD) Company Profile
名前
Amicus Therapeutics Inc
セクター
電話
(609) 662-2000
住所
47 HULFISH STREET, PRINCETON, NJ
Compare FOLD vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
FOLD
Amicus Therapeutics Inc
|
14.32 | 4.49B | 571.16M | -38.10M | -48.91M | -0.1225 |
|
VRTX
Vertex Pharmaceuticals Inc
|
467.23 | 119.47B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
761.75 | 82.49B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
840.14 | 51.25B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.39 | 42.28B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
356.10 | 38.60B | 4.98B | 69.60M | 525.67M | 0.5198 |
Amicus Therapeutics Inc Stock (FOLD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-22 | ダウングレード | Jefferies | Buy → Hold |
| 2025-12-29 | ダウングレード | Leerink Partners | Outperform → Market Perform |
| 2025-12-22 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-12-17 | 開始されました | Citigroup | Buy |
| 2025-09-18 | アップグレード | Needham | Hold → Buy |
| 2025-07-17 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-13 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2024-09-06 | 開始されました | Jefferies | Buy |
| 2024-05-30 | 開始されました | Wells Fargo | Overweight |
| 2024-05-14 | アップグレード | Guggenheim | Neutral → Buy |
| 2023-12-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2022-09-09 | 開始されました | Morgan Stanley | Equal-Weight |
| 2022-04-13 | 再開されました | Goldman | Neutral |
| 2022-01-14 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2021-11-15 | アップグレード | Stifel | Hold → Buy |
| 2021-09-30 | アップグレード | JP Morgan | Neutral → Overweight |
| 2021-07-19 | 再開されました | BTIG Research | Buy |
| 2021-05-27 | 開始されました | Needham | Hold |
| 2021-05-21 | 開始されました | UBS | Buy |
| 2021-04-14 | アップグレード | Cantor Fitzgerald | Neutral → Overweight |
| 2021-03-02 | 開始されました | Stifel | Hold |
| 2021-02-12 | ダウングレード | Cantor Fitzgerald | Overweight → Neutral |
| 2021-02-12 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-12-28 | 再開されました | Cantor Fitzgerald | Overweight |
| 2020-12-10 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-11-11 | 開始されました | Berenberg | Hold |
| 2020-06-17 | 開始されました | BTIG Research | Buy |
| 2020-02-04 | 再開されました | Cantor Fitzgerald | Overweight |
| 2019-11-12 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-06-17 | 開始されました | H.C. Wainwright | Buy |
| 2019-06-05 | 繰り返されました | Cantor Fitzgerald | Overweight |
| 2019-04-05 | 開始されました | Janney | Buy |
| 2019-01-30 | 開始されました | Cantor Fitzgerald | Overweight |
| 2018-10-29 | 開始されました | Citigroup | Neutral |
| 2018-08-17 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2017-10-06 | 再開されました | Goldman | Neutral |
| 2017-09-13 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-08-10 | 繰り返されました | Chardan Capital Markets | Buy |
| 2017-01-24 | アップグレード | Robert W. Baird | Neutral → Outperform |
| 2016-05-18 | 開始されました | BofA/Merrill | Buy |
| 2016-04-14 | 開始されました | Robert W. Baird | Neutral |
| 2016-04-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2015-09-16 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2015-06-16 | 繰り返されました | Chardan Capital Markets | Buy |
すべてを表示
Amicus Therapeutics Inc (FOLD) 最新ニュース
Metabolism Drugs Market Booming with Rapid Growth Through 2033 | - openPR.com
New York State Common Retirement Fund Raises Stock Holdings in Amicus Therapeutics, Inc. $FOLD - MarketBeat
Is Amicus Therapeutics (FOLD) Pricing Reflect Long Term Prospects In Rare Disease Treatments - Yahoo Finance
Dimerix and Amicus to commercialise DMX-200 in US - MSN
Assessing Amicus Therapeutics (FOLD) Valuation After Strong 3 Month And 1 Year Shareholder Returns - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Sees Large Volume IncreaseTime to Buy? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above Two Hundred Day Moving AverageTime to Sell? - MarketBeat
Amicus Therapeutics (NASDAQ:FOLD) Share Price Passes Above 200 Day Moving AverageShould You Sell? - MarketBeat
Jefferies Downgrades Amicus Therapeutics, Inc. (FOLD) to Buy And Lowers Price Target Amid Takeover Developments - MSN
Amicus to present new data on rare disease treatments at symposium - Investing.com Canada
Amicus Therapeutics, Inc. (FOLD): Investor Outlook with a Focus on Growth and Revenue Potential - DirectorsTalk Interviews
Amicus (FOLD) Shares New Data at WORLDSymposium 2026 - GuruFocus
Amicus Therapeutics Presents New Long-term Data for both Galafold® (migalastat) and POMBILITI® (cipaglucosidase alfa-atga) + OPFOLDA® (miglustat) at the 22nd Annual WORLDSymposium™ 2026 - The Manila Times
Analysts grow more bullish on BioMarin Pharmaceuticals Inc. (BMRN) after Amicus acquisition - MSN
BioMarin-Amicus file US antitrust paperwork, make EU referral request - MLex
BioMarin-Amicus US antitrust deadline set to expire on Feb. 20; EU referral sought - MLex
Top 3 Health Care Stocks That May Implode In Q1 - Benzinga
$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger--JHG, FOLD, RAPT, and EXAS - Sahm
California biotech BioMarin will pay $4.8 billion for Amicus Therapeutics, a rare-disease company with a presence in Philadelphia - MSN
The Right Play On BioMarin Pharmaceuticals (NASDAQ:BMRN) - Seeking Alpha
BioMarin lines up $850m bond sale to finance Amicus takeover - The Pharma Letter
Is It Time To Reassess Amicus Therapeutics (FOLD) After Last Year’s 48.9% Gain? - simplywall.st
Y Intercept Hong Kong Ltd Sells 723,540 Shares of Amicus Therapeutics, Inc. $FOLD - MarketBeat
BioMarin Weighs Amicus Deal And Billions In New Debt Financing - Sahm
BioMarin’s Amicus Deal Funding Reshapes Debt Load And Rare Disease Reach - Yahoo Finance
Fundamentals Check: Does BLKB meet Warren Buffetts criteriaTrade Entry Summary & Risk Controlled Daily Plans - baoquankhu1.vn
Will Amicus Therapeutics Inc. benefit from AI trends2025 Geopolitical Influence & Fast Moving Stock Watchlists - mfd.ru
FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside? - Yahoo Finance
Amicus Therapeutics (NASDAQ:FOLD) Lowered to Hold Rating by Zacks Research - MarketBeat
Amicus Therapeutics, Inc. (FOLD) Stock Analysis: Navigating the Upside with Strategic Growth in Rare Disease Therapeutics - DirectorsTalk Interviews
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages - MarketBeat
Market Recap: What is the long term forecast for Amicus Therapeutics Inc stockMarket Growth Report & Weekly High Momentum Picks - baoquankhu1.vn
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders - marketscreener.com
Amicus Therapeutics CEO Campbell sells $1.07 million in shares By Investing.com - Investing.com Canada
Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock - MarketBeat
Amicus Therapeutics CEO Sells 75,000 Shares - TradingView
How the $4.8B Amicus deal with BioMarin came together - The Business Journals
Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema - Finviz
Amicus Therapeutics (FOLD): Jefferies Downgrades to Hold, Lowers Price Target | FOLD Stock News - GuruFocus
Jefferies downgrades Amicus Therapeutics stock to Hold on acquisition outlook - Investing.com Canada
Jefferies Downgrades Amicus Therapeutics to Hold From Buy, Adjusts Price Target to $14.50 From $16 - marketscreener.com
How A New Price Target Is Shaping The Amicus Therapeutics (FOLD) Investment Story - Yahoo Finance
ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission - Finviz
NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies - Finviz
Novartis' Ianalumab Wins Breakthrough Therapy Tag for Sjogren's Disease - Yahoo Finance
Beat the Market the Zacks Way: Amicus, Micron, Amgen in Focus - TradingView
Amicus Therapeutics to Present at Upcoming Investor Conferences in September 2025 - FinancialContent
Amicus Therapeutics, Inc. $FOLD Holdings Boosted by Stephens Investment Management Group LLC - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in March 2025 - FinancialContent
Nordea Investment Management AB Makes New $7.84 Million Investment in Amicus Therapeutics, Inc. $FOLD - MarketBeat
FOLD Rises 136% in 6 Months: Should You Buy, Sell or Hold the Stock? - Finviz
Amicus Therapeutics Inc (FOLD) 財務データ
収益
当期純利益
現金流量
EPS
0.02%
2.62%
大文字化:
|
ボリューム (24 時間):